摘要
目的探讨不同表皮生长因子受体(EGFR)突变的晚期非小细胞肺癌(NSCLC)患者一代酪氨酸激酶抑制剂(TKI)靶向治疗的效果及预后状况。方法回顾性分析2019年1月至2022年1月安阳市人民医院收治的100例晚期NSCLC患者的临床资料,通过采集外周血,检测循环肿瘤DNA(ctDNA)中的EGFR突变情况,EGFR高表达者45例(高表达组)、低表达者55例(低表达组),两组患者均采用埃克替尼治疗,均连续治疗1个月。比较两组患者治疗后1个月的临床疗效,随访2年,比较两组患者的无进展生存期、总生存期、1年、2年的生存率,并比较其治疗期间的不良反应发生率。结果治疗后,高表达组患者的临床疗效为55.56%,明显高于低表达组的34.55%,差异有统计学意义(P<0.05);高表达组患者的无进展生存期、总生存期和第1第、第2年生存率分别为(11.10±1.40)个月、(20.33±2.61)个月、77.78%、37.78%,明显高于低表达组的(5.03±1.18)个月、(10.57±1.30)个月、54.55%、20.00%,差异均有统计学意义(P<0.05);治疗期间,高表达组、低表达组患者的不良反应的总发生率分别为73.33%、72.73%,差异无统计学意义(P>0.05)。结论EGFR高表达的NSCLC患者接受一代TKI药物埃克替尼治疗的短期临床疗效显著,且能改善患者的预后。
Objective To investigate and analyze the efficacy and prognosis of first-generation tyrosine kinase inhibitors(TKI)targeted therapy in advanced non-small cell lung cancer(NSCLC)patients with different epidermal growth factor receptor(EGFR)mutations.Methods The clinical data of 100 patients with advanced NSCLC treated in the People’s Hospital of Anyang City from January 2019 to January 2022 were retrospectively analyzed,and peripheral blood were collected to detect EGFR mutations in circulating tumor DNA(ctDNA).Among the 100 patients,45 showed high expression of EGFR(high-expression group),and 55 showed low expression(low-expression group).The two groups of patients were all treated with Icotinib,continuously for 1 month.The clinical efficacy at 1 month after treatment was compared between the two groups,and the progression-free survival,overall survival,and survival rates at 1 and 2 years of follow-up were compared between the two groups,as well as the incidence of adverse reactions during treatment.Results After treatment,the clinical efficacy in the high-expression group was 55.56%,which was significantly higher than 34.55% in the low-expression group(P<0.05).The progression-free survival,overall survival,and the 1-,2-year survival rate in the high-expression group were(11.10±1.40)months,(20.33±2.61)months,and 77.78%,37.78%,which were significantly higher than(5.03±1.18)months,(10.57±1.30)months,and 54.55%,20.00% in the low-expression group(P<0.05).During the treatment period,the total incidence of adverse reactions in the high-expression group and the low-expression group was 73.33% and 72.73%,with no statistically significant differences between the two groups(P>0.05).Conclusion For NSCLC patients with high EGFR expression,the first-generation TKI drug Icotinib has a significant effect,which can improve the prognosis of patients and is worth promoting.
作者
赵珂
王少芳
张芳芳
ZHAO Ke;WANG Shao-fang;ZHANG Fang-fang(Department of Respiratory and Critical Care Medicine,the People’s Hospital of Anyang City,Anyang 455000,Henan,CHINA)
出处
《海南医学》
CAS
2024年第11期1571-1573,共3页
Hainan Medical Journal
基金
河南省医学科技攻关计划项目(编号:2018021010)。
关键词
非小细胞肺癌
表皮生长因子受体
酪氨酸激酶抑制剂
靶向治疗
效果
预后
Non-small cell lung cancer
Epidermal growth factor receptor
Tyrosine kinase inhibitors
Targeted therapy
Effect
Prognosis
